HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

How Does Dalbavancin Measure up in the Treatment of ABSSSI?

Bruce M. Jones, PharmD, BCPS, discusses dalbavancin as an option for treating ABSSSI and the importance of patient education when using this agent.

Segment Description: Bruce M. Jones, PharmD, BCPS, infectious disease clinical pharmacy specialist and associate professor at St. Josephs/Candler Health System, discusses dalbavancin as an option for treating ABSSSI and the importance of patient education when using this agent.

Interview Transcript (modified slightly for readability):

“I think dalbavancin is a great option out there. The way I look at it is being able to give a full course of therapy in a 30-minute intravenous (IV) infusion is great, especially for certain patient populations. You’re able to avoid a central line—a PICC—and many times, you don’t have to do therapeutic drug monitoring associated with vancomycin. Vancomycin being a weight-based dosing option, it’s very hard to do outpatient logistically.

You don’t have the interaction with any of the coagulation tasks out there; you don’t have drug-drug interactions. Being able to give 1 dose and fully treat a patient, it also takes compliance and adherence out of the picture as well.

I think the biggest con to this drug is making sure that you educate patients and you give proper follow-up to them. Outside of that, in terms of treating, I have seen great results personally with this agent.”